ScoreWhy is CytomX Therapeutics, Inc. ?
1
With a fall in Net Sales of -25.71%, the company declared Very Negative results in Jun 25
- The company has declared negative results in Jan 70 after 2 consecutive negative quarters
- CASH AND EQV(HY) Lowest at USD 237.97 MM
- NET SALES(Q) Lowest at USD 18.66 MM
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is CytomX Therapeutics, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
CytomX Therapeutics, Inc.
231.71%
0.96
161.16%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
10.62%
EBIT Growth (5y)
20.36%
EBIT to Interest (avg)
-30.99
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-2.98
Sales to Capital Employed (avg)
1.32
Tax Ratio
0.56%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
84.88%
ROCE (avg)
0
ROE (avg)
41.52%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
10
Industry P/E
Price to Book Value
16.60
EV to EBIT
9.49
EV to EBITDA
9.07
EV to Capital Employed
-6.89
EV to Sales
2.31
PEG Ratio
0.14
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
166.09%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend16What is working for the Company
ROCE(HY)
Highest at 108.21%
RAW MATERIAL COST(Y)
Fallen by 0.03% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -126.1 %
DEBTORS TURNOVER RATIO(HY)
Highest at 60.77 times
PRE-TAX PROFIT(Q)
At USD -0.09 MM has Grown at 98.6%
NET PROFIT(Q)
At USD -0.15 MM has Grown at 97.64%
-4What is not working for the Company
CASH AND EQV(HY)
Lowest at USD 237.97 MM
NET SALES(Q)
Lowest at USD 18.66 MM
Here's what is working for CytomX Therapeutics, Inc.
Pre-Tax Profit
At USD -0.09 MM has Grown at 98.6%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
At USD -0.15 MM has Grown at 97.64%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Debt-Equity Ratio
Lowest at -126.1 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Debtors Turnover Ratio
Highest at 60.77 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by 0.03% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for CytomX Therapeutics, Inc.
Net Sales
At USD 18.66 MM has Fallen at -25.71%
Year on Year (YoY)MOJO Watch
Near term sales trend is very negative
Net Sales (USD MM)
Net Sales
Lowest at USD 18.66 MM
in the last five periodsMOJO Watch
Near term sales trend is negative
Net Sales (USD MM)
Cash and Eqv
Lowest at USD 237.97 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
